Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia

Journal of Clinical Oncology

Volumn 28, Issue 3, 2010, Pages 405-411

  Lim, Ziyi ^a   Brand, Ronald ^a   Martino, Rodrigo ^a   Van Biezen, Anja ^a   Finke, Jürgen ^a   Bacigalupo, Andrea ^a   Beelen, Dietrich ^a   Devergie, Agnes ^a   Alessandrino, Emilio ^a   Willemze, Roel ^a   Ruutu, Tapani ^a   Boogaerts, Marc ^a   Falda, Michele ^a   Jouet, Jean Pierre ^a   Niederwieser, Dietger ^a   Kroger, Nicolaus ^a   Mufti, Ghulam J ^a   De Witte, Theo M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; HLA ANTIGEN; MELPHALAN; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE COURSE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; ORGAN DONOR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; RECIPIENT; REDUCED INTENSITY CONDITIONING; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; RETROSPECTIVE STUDY; SIBLING; TREATMENT OUTCOME; WHOLE BODY RADIATION; AGE; ALLOTRANSPLANTATION; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MULTICENTER STUDY;

AGE FACTORS; AGED; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 75749124680     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.21.8073     Document Type: Article

References (31)

1. Anderson JE, Anasetti C, Appelbaum FR, et al: Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol 93:59-67, 1996
2. Arnold R, de Witte T, van Biezen A, et al: Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: An EBMT survey. European Blood and Marrow Transplantation Group Bone Marrow Transplant 21:1213-1216, 1998
3. Castro-Malaspina H, Harris RE, Gajewski J, et al: Unrelated donor marrow transplantation for myelodysplastic syndromes: Outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 99:1943-1951, 2002
4. Copelan EA, Penza SL, Elder PJ, et al: Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation. Bone Marrow Transplant 25: 1219-1222, 2000
5. Cutler CS, Lee SJ, Greenberg P, et al: A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104:579-585, 2004
6. Martino R, Iacobelli S, Brand R, et al: Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108:836-846, 2006
7. Yakoub-Agha I, de La Salmoniere P, Ribaud P, et al: Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: A long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol 18:963-971, 2000
8. Slavin S, Nagler A, Naparstek E, et al: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763, 1998
9. Deeg HJ, Storer B, Slattery JT, et al: Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100:1201-1207, 2002
10. Gratwohl A, Baldomero H, Passweg J, et al: Hematopoietic stem cell transplantation for hematological malignancies in Europe. Leukemia 17:941-959, 2003
11. Alyea EP, Kim HT, Ho V, et al: Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 12:1047-1055, 2006
12. de Lima M, Anagnostopoulos A, Munsell M, et al: Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104:865-872, 2004
13. Crawley C, Iacobelli S, Bjorkstrand B, et al: Reduced-intensity conditioning for myeloma: Lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 109: 3588-3594, 2007
14. Martino R, Caballero MD, Simon JA, et al: Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 100:2243-2245, 2002
15. de Witte T, Hermans J, Vossen J, et al: Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110:620-630, 2000
16. Alyea EP, Kim HT, Ho V, et al: Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105:1810-1814, 2005
17. Alamo J, Shahjahan M, Lazarus HM, et al: Comorbidity indices in hematopoietic stem cell transplantation: A new report card. Bone Marrow Transplant 36:475-479, 2005
18. Artz AS, Pollyea DA, Kocherginsky M, et al: Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 12:954-964, 2006
19. Sorror ML, Maris MB, Storb R, et al: Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 106:2912-2919, 2005
20. Lim ZY, Ho AY, Ingram W, et al: Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol 135: 201-209, 2006
21. Scott BL, Sandmaier BM, Storer B, et al: Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: A retrospective analysis. Leukemia 20:128-135, 2006
22. Scott BL, Storer B, Loken MR, et al: Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 11:65-73, 2005
23. De Witte T, Muus P, De Pauw B, et al: Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer 66:831-837, 1990
24. Parker JE, Pagliuca A, Mijovic A, et al: Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia Br J Haematol 99:939-944, 1997
25. Bertz H, Potthoff K, Finke J: Allogeneic stemcell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 21:1480-1484, 2003
26. Spyridonidis A, Bertz H, Ihorst G, et al: Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (> or = 60 years) with active myeloid malignancies. Blood 105: 4147-4148, 2005
27. List A, Dewald G, Bennett J, et al: Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456-1465, 2006
28. Silverman LR, Mufti GJ: Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nat Clin Pract Oncol 2:S12-S23, 2005 (suppl 1)
29. Kantarjian H, Issa JP, Rosenfeld CS, et al: Decitabine improves patient outcomes in myelodys-plastic syndromes: Results of a phase III randomized study. Cancer 106:1794-1803, 2006
30. Jabbour E, Giralt S, Kantarjian H, et al: Lowdose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 115:1899-1905, 2009
31. Ho AY, Pagliuca A, Kenyon M, et al: Reduced-intensity allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukaemia with multilineage dysplasia using fludarabine, busulphan and alemtuzumab (CAMPATH-1H)(FBC) conditioning. Blood 104:1616-1623, 2004